A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of ...
By Stephen Smoot President Donald Trump has moved back into his comfort zone on foreign policy - working on a real estate deal for Greenland that would even outstrip Thomas Jefferson’s Louisiana ...
Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirement; Evaxion has cu ...